The global prostate cancer diagnostics market size is expected to reach USD 13.16 billion by 2030, expanding at a CAGR of 6.4% from 2024 to 2030. Supportive government initiatives, increasing disease prevalence across the globe, and a rise in the prevalence of prostate cancer coupled with technological advancements in confirmatory diagnostic tests are the major drivers for this market. ![Global Prostate Cancer Diagnostics Market]( "Global Prostate Cancer Diagnostics Market")
A rise in favorable government initiatives to enhance research associated with a focus on effective diagnosis and treatment is expected to boost market growth during the forecast period. For instance, the National Cancer Institute initiated the study titled ‘Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress’ (RESPOND). This study is the largest collaboration to research the non-biological and biological factors that are associated with prostate cancer in African-American men. It was launched by the National Institute on Minority Health and NCI and Health Disparities in collaboration with the Prostate Cancer Foundation with a funding of USD 26.0 million.
Researchers from the University of Norfolk and East Anglia along with Norwich University Hospital developed a non-invasive urine test that helps in identifying men that are up to 8 times less likely to need a treatment procedure within 5 years of diagnosis. Technological advancements such as these are also anticipated to impact market potential in the near future.
Additionally, researchers at Karolinska and KTH Institute concluded that the use of artificial intelligence in spatial transcriptomics can aid in the early detection of prostate cancer, thereby, improving clinical diagnosis and treatment. Spatial transcriptomics is a method that usually combines quantitative analysis of active genes and their histology and can aid in effective disease diagnosis.
A rise in favorable government initiatives to enhance research associated with a focus on effective diagnosis and treatment is expected to boost market growth during the forecast period. For instance, the National Cancer Institute initiated the study titled ‘Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress’ (RESPOND). This study is the largest collaboration to research the non-biological and biological factors that are associated with prostate cancer in African-American men. It was launched by the National Institute on Minority Health and NCI and Health Disparities in collaboration with the Prostate Cancer Foundation with a funding of USD 26.0 million.
Researchers from the University of Norfolk and East Anglia along with Norwich University Hospital developed a non-invasive urine test that helps in identifying men that are up to 8 times less likely to need a treatment procedure within 5 years of diagnosis. Technological advancements such as these are also anticipated to impact market potential in the near future.
Additionally, researchers at Karolinska and KTH Institute concluded that the use of artificial intelligence in spatial transcriptomics can aid in the early detection of prostate cancer, thereby, improving clinical diagnosis and treatment. Spatial transcriptomics is a method that usually combines quantitative analysis of active genes and their histology and can aid in effective disease diagnosis.
Prostate Cancer Diagnostics Market Report Highlights
- Confirmatory tests held the largest market share in 2023. The segment holds largest market share by 66.4%. Confirmatory tests include the PCA3 test, Transrectal Ultrasound (TRUS), and biopsy of the affected portion
- Based on end use, the market is segmented into hospitals, outpatient facilities, home care, and research & manufacturing. In 2023, the Outpatient Facilities segment dominated the market. Outpatient Facilities have revolutionized and developed more comfortable consulting and treatment systems with the acquisition and experience of the licensed physician
- The North American region holds the largest market share owing to rising prevalence and the rise in government initiatives to enhance diagnosis
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test Type
1.2.2. Type
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia-Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Test Type
1.2.2. Type
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia-Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test Type
2.2.2. Type
2.2.3. End Use
2.2.4. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Test Type
2.2.2. Type
2.2.3. End Use
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of prostate cancer
3.2.1.2. Increasing global geriatric population
3.2.1.3. Technological advancements in the field of cancer diagnostics
3.2.2. Market restraint analysis
3.2.2.1. High cost of diagnostics
3.3. Prostate Cancer Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of prostate cancer
3.2.1.2. Increasing global geriatric population
3.2.1.3. Technological advancements in the field of cancer diagnostics
3.2.2. Market restraint analysis
3.2.2.1. High cost of diagnostics
3.3. Prostate Cancer Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Prostate Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
4.1. Test Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Preliminary Tests
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. PSA Tests
4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Free PSA Test
4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Total PSA Test
4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Other Preliminary Tests
4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Confirmatory Tests
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Pca3 Test
4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Trans-Rectal Ultrasound
4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Biopsy Test
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2. Segment Dashboard
4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Preliminary Tests
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. PSA Tests
4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Free PSA Test
4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Total PSA Test
4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Other Preliminary Tests
4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Confirmatory Tests
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Pca3 Test
4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Trans-Rectal Ultrasound
4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Biopsy Test
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis
5.1. Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Prostate Cancer Diagnostics Market by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Adenocarcinoma
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Interstitial Cell Carcinoma
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Other
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2. Segment Dashboard
5.3. Global Prostate Cancer Diagnostics Market by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Adenocarcinoma
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Interstitial Cell Carcinoma
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Other
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Prostate Cancer Diagnostics Market: End Use Estimates & Trend Analysis
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Outpatient Facilities
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Home Care
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Research & Manufacturing
6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.2. Segment Dashboard
6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Outpatient Facilities
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Home Care
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Research & Manufacturing
6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia-Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia-Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. MDx Health
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Test Type benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Myriad Genetics, Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Test Type benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Abbott Laboratories
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Test Type benchmarking
8.3.6.4. Strategic initiatives
8.3.7. F. Hoffman-La Roche AG
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Test Type benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Bayer AG
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Test Type benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Siemens Healthcare GmbH
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Test Type benchmarking
8.3.9.4. Strategic initiatives
8.3.10. OPKO Health, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Test Type benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Genomic Health.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Test Type benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Pfizer Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Test Type benchmarking
8.3.12.4. Strategic initiatives
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. MDx Health
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Test Type benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Myriad Genetics, Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Test Type benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Abbott Laboratories
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Test Type benchmarking
8.3.6.4. Strategic initiatives
8.3.7. F. Hoffman-La Roche AG
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Test Type benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Bayer AG
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Test Type benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Siemens Healthcare GmbH
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Test Type benchmarking
8.3.9.4. Strategic initiatives
8.3.10. OPKO Health, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Test Type benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Genomic Health.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Test Type benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Pfizer Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Test Type benchmarking
8.3.12.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 3 North America Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 4 North America Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 5 North America Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 6 U.S. Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 7 U.S. Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 8 U.S. Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 9 Canada Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 10 Canada Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 11 Canada Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 12 Europe Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 13 Europe Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 14 Europe Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 15 Europe Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 16 Germany Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 17 Germany Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 18 Germany Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 19 UK Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 20 UK Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 21 UK Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 22 France Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 23 France Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 24 France Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 25 Italy Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 26 Italy Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 27 Italy Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 28 Spain Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 29 Spain Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 30 Spain Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 31 Denmark Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 32 Denmark Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 33 Denmark Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 34 Sweden Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 35 Sweden Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 36 Sweden Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 37 Norway Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 38 Norway Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 39 Norway Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 40 Asia-Pacific Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 41 Asia-Pacific Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 42 Asia-Pacific Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 43 Asia-Pacific Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 44 China Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 45 China Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 46 China Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 47 Japan Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 48 Japan Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 49 Japan Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 50 India Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 51 India Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 52 India Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 53 South Korea Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 54 South Korea Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 55 South Korea Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 56 Australia Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 57 Australia Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 58 Australia Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 59 Thailand Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 60 Thailand Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 61 Thailand Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 62 Latin America Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 63 Latin America Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 64 Latin America Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 65 Latin America Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 66 Brazil Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 67 Brazil Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 68 Brazil Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 69 Mexico Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 70 Mexico Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 71 Mexico Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 72 Argentina Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 73 Argentina Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 74 Argentina Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 75 MEA Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 76 MEA Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 77 MEA Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 78 MEA Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 79 South Africa Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 80 South Africa Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 81 South Africa Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 82 Saudi Arabia Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 83 Saudi Arabia Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 84 Saudi Arabia Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 85 UAE Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 86 UAE Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 87 UAE Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 88 Kuwait Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 89 Kuwait Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 90 Kuwait Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 2 North America Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 3 North America Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 4 North America Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 5 North America Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 6 U.S. Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 7 U.S. Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 8 U.S. Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 9 Canada Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 10 Canada Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 11 Canada Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 12 Europe Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 13 Europe Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 14 Europe Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 15 Europe Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 16 Germany Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 17 Germany Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 18 Germany Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 19 UK Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 20 UK Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 21 UK Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 22 France Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 23 France Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 24 France Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 25 Italy Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 26 Italy Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 27 Italy Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 28 Spain Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 29 Spain Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 30 Spain Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 31 Denmark Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 32 Denmark Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 33 Denmark Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 34 Sweden Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 35 Sweden Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 36 Sweden Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 37 Norway Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 38 Norway Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 39 Norway Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 40 Asia-Pacific Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 41 Asia-Pacific Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 42 Asia-Pacific Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 43 Asia-Pacific Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 44 China Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 45 China Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 46 China Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 47 Japan Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 48 Japan Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 49 Japan Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 50 India Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 51 India Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 52 India Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 53 South Korea Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 54 South Korea Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 55 South Korea Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 56 Australia Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 57 Australia Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 58 Australia Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 59 Thailand Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 60 Thailand Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 61 Thailand Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 62 Latin America Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 63 Latin America Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 64 Latin America Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 65 Latin America Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 66 Brazil Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 67 Brazil Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 68 Brazil Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 69 Mexico Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 70 Mexico Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 71 Mexico Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 72 Argentina Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 73 Argentina Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 74 Argentina Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 75 MEA Prostate Cancer Diagnostics market, by region, 2018-2030 (USD Million)
Table 76 MEA Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 77 MEA Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 78 MEA Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 79 South Africa Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 80 South Africa Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 81 South Africa Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 82 Saudi Arabia Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 83 Saudi Arabia Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 84 Saudi Arabia Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 85 UAE Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 86 UAE Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 87 UAE Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
Table 88 Kuwait Prostate Cancer Diagnostics market, by test type, 2018-2030 (USD Million)
Table 89 Kuwait Prostate Cancer Diagnostics market, by type, 2018-2030 (USD Million)
Table 90 Kuwait Prostate Cancer Diagnostics market, by end use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Prostate Cancer Diagnostics market: market outlook
Figure 14 Prostate Cancer Diagnostics competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Prostate Cancer Diagnostics market driver impact
Figure 20 Prostate Cancer Diagnostics market restraint impact
Figure 21 Prostate Cancer Diagnostics market strategic initiatives analysis
Figure 22 Prostate Cancer Diagnostics market: Test Type movement analysis
Figure 23 Prostate Cancer Diagnostics market: Test Type outlook and key takeaways
Figure 24 Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 25 PSA Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 26 Free PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 27 Total PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 28 Other Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 29 Confirmatory Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 30 Pca3 Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 31 Trans-Rectal Ultrasound Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 32 Biopsy Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 33 Prostate Cancer Diagnostics Market: Type movement Analysis
Figure 34 Prostate Cancer Diagnostics market: Type outlook and key takeaways
Figure 35 Adenocarcinoma market estimates and forecasts, 2018-2030
Figure 36 Interstitial Cell Carcinoma market estimates and forecasts,2018-2030
Figure 37 Other market estimates and forecasts,2018-2030
Figure 38 Prostate Cancer Diagnostics market: End Use movement analysis
Figure 39 Prostate Cancer Diagnostics market: End Use outlook and key takeaways
Figure 40 Hospitals market estimates and forecasts, 2018-2030
Figure 41 Outpatient Facilities market estimates and forecasts,2018-2030
Figure 42 Home Care market estimates and forecasts, 2018-2030
Figure 43 Research & Manufacturing market estimates and forecasts,2018-2030
Figure 44 Global Prostate Cancer Diagnostics market: Regional movement analysis
Figure 45 Global Prostate Cancer Diagnostics market: Regional outlook and key takeaways
Figure 46 Global Prostate Cancer Diagnostics market share and leading players
Figure 47 North America market share and leading players
Figure 48 Europe market share and leading players
Figure 49 Asia-Pacific market share and leading players
Figure 50 Latin America market share and leading players
Figure 51 Middle East & Africa market share and leading players
Figure 52 North America: SWOT
Figure 53 Europe SWOT
Figure 54 Asia-Pacific SWOT
Figure 55 Latin America SWOT
Figure 56 MEA SWOT
Figure 57 North America, by country
Figure 58 North America
Figure 59 North America market estimates and forecasts, 2018-2030
Figure 60 U.S.
Figure 61 U.S. market estimates and forecasts, 2018-2030
Figure 62 Canada
Figure 63 Canada market estimates and forecasts, 2018-2030
Figure 64 Europe
Figure 65 Europe market estimates and forecasts, 2018-2030
Figure 66 UK
Figure 67 UK market estimates and forecasts, 2018-2030
Figure 68 Germany
Figure 69 Germany market estimates and forecasts, 2018-2030
Figure 70 France
Figure 71 France market estimates and forecasts, 2018-2030
Figure 72 Italy
Figure 73 Italy market estimates and forecasts, 2018-2030
Figure 74 Spain
Figure 75 Spain market estimates and forecasts, 2018-2030
Figure 76 Denmark
Figure 77 Denmark market estimates and forecasts, 2018-2030
Figure 78 Sweden
Figure 79 Sweden market estimates and forecasts, 2018-2030
Figure 80 Norway
Figure 81 Norway market estimates and forecasts, 2018-2030
Figure 82 Asia-Pacific
Figure 83 Asia-Pacific market estimates and forecasts, 2018-2030
Figure 84 China
Figure 85 China market estimates and forecasts, 2018-2030
Figure 86 Japan
Figure 87 Japan market estimates and forecasts, 2018-2030
Figure 88 India
Figure 89 India market estimates and forecasts, 2018-2030
Figure 90 Thailand
Figure 91 Thailand market estimates and forecasts, 2018-2030
Figure 92 South Korea
Figure 93 South Korea market estimates and forecasts, 2018-2030
Figure 94 Australia
Figure 95 Australia market estimates and forecasts, 2018-2030
Figure 96 Latin America
Figure 97 Latin America market estimates and forecasts, 2018-2030
Figure 98 Brazil
Figure 99 Brazil market estimates and forecasts, 2018-2030
Figure 100 Mexico
Figure 101 Mexico market estimates and forecasts, 2018-2030
Figure 102 Argentina
Figure 103 Argentina market estimates and forecasts, 2018-2030
Figure 104 Middle East and Africa
Figure 105 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 106 South Africa
Figure 107 South Africa market estimates and forecasts, 2018-2030
Figure 108 Saudi Arabia
Figure 109 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 110 UAE
Figure 111 UAE market estimates and forecasts, 2018-2030
Figure 112 Kuwait
Figure 113 Kuwait market estimates and forecasts, 2018-2030
Figure 114 Market share of key market players - Prostate Cancer Diagnostics market
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Prostate Cancer Diagnostics market: market outlook
Figure 14 Prostate Cancer Diagnostics competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Prostate Cancer Diagnostics market driver impact
Figure 20 Prostate Cancer Diagnostics market restraint impact
Figure 21 Prostate Cancer Diagnostics market strategic initiatives analysis
Figure 22 Prostate Cancer Diagnostics market: Test Type movement analysis
Figure 23 Prostate Cancer Diagnostics market: Test Type outlook and key takeaways
Figure 24 Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 25 PSA Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 26 Free PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 27 Total PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 28 Other Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 29 Confirmatory Tests Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 30 Pca3 Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 31 Trans-Rectal Ultrasound Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 32 Biopsy Test Prostate Cancer Diagnostics market estimates and forecast, 2018-2030
Figure 33 Prostate Cancer Diagnostics Market: Type movement Analysis
Figure 34 Prostate Cancer Diagnostics market: Type outlook and key takeaways
Figure 35 Adenocarcinoma market estimates and forecasts, 2018-2030
Figure 36 Interstitial Cell Carcinoma market estimates and forecasts,2018-2030
Figure 37 Other market estimates and forecasts,2018-2030
Figure 38 Prostate Cancer Diagnostics market: End Use movement analysis
Figure 39 Prostate Cancer Diagnostics market: End Use outlook and key takeaways
Figure 40 Hospitals market estimates and forecasts, 2018-2030
Figure 41 Outpatient Facilities market estimates and forecasts,2018-2030
Figure 42 Home Care market estimates and forecasts, 2018-2030
Figure 43 Research & Manufacturing market estimates and forecasts,2018-2030
Figure 44 Global Prostate Cancer Diagnostics market: Regional movement analysis
Figure 45 Global Prostate Cancer Diagnostics market: Regional outlook and key takeaways
Figure 46 Global Prostate Cancer Diagnostics market share and leading players
Figure 47 North America market share and leading players
Figure 48 Europe market share and leading players
Figure 49 Asia-Pacific market share and leading players
Figure 50 Latin America market share and leading players
Figure 51 Middle East & Africa market share and leading players
Figure 52 North America: SWOT
Figure 53 Europe SWOT
Figure 54 Asia-Pacific SWOT
Figure 55 Latin America SWOT
Figure 56 MEA SWOT
Figure 57 North America, by country
Figure 58 North America
Figure 59 North America market estimates and forecasts, 2018-2030
Figure 60 U.S.
Figure 61 U.S. market estimates and forecasts, 2018-2030
Figure 62 Canada
Figure 63 Canada market estimates and forecasts, 2018-2030
Figure 64 Europe
Figure 65 Europe market estimates and forecasts, 2018-2030
Figure 66 UK
Figure 67 UK market estimates and forecasts, 2018-2030
Figure 68 Germany
Figure 69 Germany market estimates and forecasts, 2018-2030
Figure 70 France
Figure 71 France market estimates and forecasts, 2018-2030
Figure 72 Italy
Figure 73 Italy market estimates and forecasts, 2018-2030
Figure 74 Spain
Figure 75 Spain market estimates and forecasts, 2018-2030
Figure 76 Denmark
Figure 77 Denmark market estimates and forecasts, 2018-2030
Figure 78 Sweden
Figure 79 Sweden market estimates and forecasts, 2018-2030
Figure 80 Norway
Figure 81 Norway market estimates and forecasts, 2018-2030
Figure 82 Asia-Pacific
Figure 83 Asia-Pacific market estimates and forecasts, 2018-2030
Figure 84 China
Figure 85 China market estimates and forecasts, 2018-2030
Figure 86 Japan
Figure 87 Japan market estimates and forecasts, 2018-2030
Figure 88 India
Figure 89 India market estimates and forecasts, 2018-2030
Figure 90 Thailand
Figure 91 Thailand market estimates and forecasts, 2018-2030
Figure 92 South Korea
Figure 93 South Korea market estimates and forecasts, 2018-2030
Figure 94 Australia
Figure 95 Australia market estimates and forecasts, 2018-2030
Figure 96 Latin America
Figure 97 Latin America market estimates and forecasts, 2018-2030
Figure 98 Brazil
Figure 99 Brazil market estimates and forecasts, 2018-2030
Figure 100 Mexico
Figure 101 Mexico market estimates and forecasts, 2018-2030
Figure 102 Argentina
Figure 103 Argentina market estimates and forecasts, 2018-2030
Figure 104 Middle East and Africa
Figure 105 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 106 South Africa
Figure 107 South Africa market estimates and forecasts, 2018-2030
Figure 108 Saudi Arabia
Figure 109 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 110 UAE
Figure 111 UAE market estimates and forecasts, 2018-2030
Figure 112 Kuwait
Figure 113 Kuwait market estimates and forecasts, 2018-2030
Figure 114 Market share of key market players - Prostate Cancer Diagnostics market
Companies Mentioned
- MDx Health
- Myriad Genetics, Inc.
- Abbott Laboratories
- F. Hoffman-La Roche AG
- Bayer AG
- Siemens Healthcare GmbH
- OPKO Health, Inc.
- Genomic Health.
- Pfizer Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 152 |
| Published | December 2023 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 8.56 Billion |
| Forecasted Market Value ( USD | $ 13.16 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
